# US 2024/0197667 A1 · Systems and methods for treating vitiligo using ethyl pyruvate and other compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197667 A1
- Document ID: US20240197667A1
- Status: Published application
- Kind: A1
- Application number: 18/286,549
- Filed: 2022-04-13
- Published: 2024-06-20
- Earliest claimed: 2021-04-14
- Assignees: Transdermal Biotechnology, Inc.
- Applicants: Transdermal Biotechnology, Inc.
- Inventors: Nicholas V. Perricone
- Web page: https://patentgrep.com/patent/US20240197667A1

## CPC

- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure generally relates to systems and methods for treating vitiligo. In one set of embodiments, the present disclosure comprises a composition comprising ethyl pyruvate. The composition may be formulated for application to the skin of a subject, for instance, as a gel, lotion, cream, ointment, soap, or stick. In some cases, the composition may comprise a lecithin, such as phosphatidylcholine. In certain embodiments. the lecithin is present as a liquid crystal, and/or in liposomes, micelles, or other vesicles. Other aspects of the present disclosure are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

## Claims

### Claim 1

A method, comprising:
applying, to the skin of a subject having vitiligo, a topical composition comprising ethyl pyruvate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ethyl pyruvate is present at less than about 0.2% by weight.

### Claim 3 (depends on 1, 2)

The method of any one of claim 1 or 2, wherein the composition comprises a gel, lotion, cream, ointment, soap, or stick.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the formulation is substantially transparent.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the composition comprises a first phase and a second phase.

### Claim 6 (depends on 5)

The method of claim 5, wherein the formulation comprises an emulsion of the first phase and a second phase.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the first phase forms discrete vesicles contained within the second phase.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the first phase forms liposomes within the second phase.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the first phase forms multilamellar liposomes within the second phase.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the formulation comprises a liquid crystal structure of the first phase and a second phase.

### Claim 11 (depends on 10)

The method of claim 10, wherein at least a portion of the liquid crystal structure is multilamellar.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the composition further comprises lecithin.

### Claim 13 (depends on 12)

The method of claim 12, wherein the lecithin is present at at least about 0.25% by weight of the formulation.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the lecithin is present at at least about 1% by weight of the formulation.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the lecithin is present at at least about 10% by weight of the formulation.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the lecithin is present at at least about 30% by weight of the formulation.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the lecithin is present at at least about 60% by weight of the formulation.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the lecithin comprises phosphatidylcholine.

### Claim 19 (depends on 18)

The method of claim 18, wherein at least some of the phosphatidylcholine comprises a phosphatidylcholine comprising a stearic diglyceride linked to a choline ester of a phosphoric acid.

### Claim 20 (depends on 18, 19)

The method of any one of claim 18 or 19, wherein at least some of the phosphatidylcholine comprises a phosphatidylcholine comprising a palmitic diglyceride linked to a choline ester of a phosphoric acid.

### Claim 21 (depends on 18, 19, 20)

The method of any one of claims 18-20, wherein at least some of the phosphatidylcholine comprises a phosphatidylcholine comprising an oleic diglyceride linked to a choline ester of a phosphoric acid.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the lecithin comprises polyenylphosphatidylcholine.

### Claim 23 (depends on 22)

The method of claim 22, wherein the polyenylphosphatidylcholine is present at between 0% and about 15% by weight of the formulation.

### Claim 24 (depends on 22, 23)

The method of any one of claim 22 or 23, wherein the polyenylphosphatidylcholine comprises linoleic acid.

### Claim 25 (depends on 22, 23, 24)

The method of any one of claims 22-24, wherein the polyenylphosphatidylcholine comprises dilinoleoylphosphatidylcholine.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the formulation further comprises an emulsifier.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the formulation further comprises a fatty acid ester.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the formulation further comprises ascorbate palmitate.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein the formulation further comprises isopropyl palmitate.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the formulation further comprises a transdermal penetration enhancer.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the formulation further comprises 1,3-dimethyl-2-imidazolidinone.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the formulation further comprises 1,2-propanediol.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-32, wherein the composition has a viscosity of at least about 20,000 cP.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the subject is human.

### Claim 35

A composition for transdermal delivery, the composition comprising:
a transdermal formulation comprising a first phase and a second phase, the first phase comprising water and ethyl pyruvate, the second phase being substantially immiscible with the first phase, the formulation further comprising a surfactant comprising lecithin.

### Claim 36 (depends on 35)

The composition of claim 35, wherein the ethyl pyruvate is present at less than about 0.2% by weight.

### Claim 37 (depends on 35, 36)

The composition of any one of claim 35 or 36, wherein the composition comprises a gel, lotion, cream, ointment, soap, or stick.

### Claim 38 (depends on 35, 36, 37)

The composition of any one of claims 35-37, wherein the formulation is substantially transparent.

### Claim 39 (depends on 35, 36, 37, 38)

The composition of any one of claims 35-38, wherein the composition comprises a first phase and a second phase.

### Claim 40 (depends on 39)

The composition of any one of claims 39, wherein the formulation comprises an emulsion of the first phase and a second phase.

### Claim 41 (depends on 39, 40)

The composition of any one of claim 39 or 40, wherein the first phase forms discrete vesicles contained within the second phase.

### Claim 42 (depends on 39, 40, 41)

The composition of any one of claims 39-41, wherein the first phase forms liposomes within the second phase.

### Claim 43 (depends on 39, 40, 41, 42)

The composition of any one of claims 39-42, wherein the first phase forms multilamellar liposomes within the second phase.

### Claim 44 (depends on 39, 40, 41, 42, 43)

The composition of any one of claims 39-43, wherein the formulation comprises a liquid crystal structure of the first phase and a second phase.

### Claim 45 (depends on 44)

The composition of claim 44, wherein at least a portion of the liquid crystal structure is multilamellar.

### Claim 46 (depends on 45)

The composition of claim 45, wherein the composition further comprises lecithin.

### Claim 47 (depends on 46)

The composition of claim 46, wherein the lecithin is present at at least about 0.25% by weight of the formulation.

### Claim 48 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The composition of any one of claims 35-47, wherein the lecithin is present at at least about 1% by weight of the formulation.

### Claim 49 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The composition of any one of claims 35-48, wherein the lecithin is present at at least about 10% by weight of the formulation.

### Claim 50 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The composition of any one of claims 35-49, wherein the lecithin is present at at least about 30% by weight of the formulation.

### Claim 51 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The composition of any one of claims 35-50, wherein the lecithin is present at at least about 60% by weight of the formulation.

### Claim 52 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The composition of any one of claims 35-51, wherein the lecithin comprises phosphatidylcholine.

### Claim 53 (depends on 52)

The composition of claim 52, wherein at least some of the phosphatidylcholine comprises a phosphatidylcholine comprising a stearic diglyceride linked to a choline ester of a phosphoric acid.

### Claim 54 (depends on 52)

The composition of claim 52, wherein at least some of the phosphatidylcholine comprises a phosphatidylcholine comprising a palmitic diglyceride linked to a choline ester of a phosphoric acid.

### Claim 55 (depends on 52, 53)

The composition of any one of claims 52-53, wherein at least some of the phosphatidylcholine comprises a phosphatidylcholine comprising an oleic diglyceride linked to a choline ester of a phosphoric acid.

### Claim 56 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The composition of any one of claims 35-54, wherein the lecithin comprises polyenylphosphatidylcholine.

### Claim 57 (depends on 56)

The composition of claim 56, wherein the polyenylphosphatidylcholine is present at between 0% and about 15% by weight of the formulation.

### Claim 58 (depends on 57)

The composition of claim 57, wherein the polyenylphosphatidylcholine comprises linoleic acid.

### Claim 59 (depends on 57, 58)

The composition of any one of claim 57 or 58, wherein the polyenylphosphatidylcholine comprises dilinoleoylphosphatidylcholine.

### Claim 60 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The composition of any one of claims 35-59, wherein the formulation further comprises an emulsifier.

### Claim 61 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The composition of any one of claims 35-60, wherein the formulation further comprises a fatty acid ester.

### Claim 62 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The composition of any one of claims 35-61, wherein the formulation further comprises ascorbate palmitate.

### Claim 63 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The composition of any one of claims 35-62, wherein the formulation further comprises isopropyl palmitate.

### Claim 64 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The composition of any one of claims 35-63, wherein the formulation further comprises a transdermal penetration enhancer.

### Claim 65 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The composition of any one of claims 35-64, wherein the formulation further comprises 1,3-dimethyl-2-imidazolidinone.

### Claim 66 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The composition of any one of claims 35-65, wherein the formulation further comprises 1,2-propanediol.

### Claim 67 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The composition of any one of claims 35-66, wherein the composition has a viscosity of at least about 20,000 cP.

### Claim 68

A composition for transdermal delivery, the composition comprising:
a cream comprising a first phase and a second phase, the first phase comprising water and ethyl pyruvate, the second phase being substantially immiscible with the first phase, the cream further comprising polyenylphosphatidylcholine stabilizing the first phase and the second phase.

### Claim 69 (depends on 68)

The composition of claim 68, wherein the ethyl pyruvate is present at less than about 0.2% by weight.

### Claim 70 (depends on 68, 69)

The composition of any one of claim 68 or 69, wherein the composition comprises a gel, lotion, cream, ointment, soap, or stick.

### Claim 71 (depends on 68, 69, 70)

The composition of any one of claims 68-70, wherein the formulation is substantially transparent.

### Claim 72 (depends on 68, 69, 70, 71)

The composition of any one of claims 68-71, wherein the composition comprises a first phase and a second phase.

### Claim 73 (depends on 72)

The composition of claim 72, wherein the formulation comprises an emulsion of the first phase and a second phase.

### Claim 74 (depends on 68, 69, 70, 71, 72, 73)

The composition of any one of claims 68-73, wherein the first phase forms discrete vesicles contained within the second phase.

### Claim 75 (depends on 68, 69, 70, 71, 72, 73, 74)

The composition of any one of claims 68-74, wherein the first phase forms liposomes within the second phase.

### Claim 76 (depends on 68, 69, 70, 71, 72, 73, 74, 75)

The composition of any one of claims 68-75, wherein the first phase forms multilamellar liposomes within the second phase.

### Claim 77 (depends on 76)

The composition of claim 76, wherein the formulation comprises a liquid crystal structure of the first phase and a second phase.

### Claim 78 (depends on 77)

The composition of claim 77, wherein at least a portion of the liquid crystal structure is multilamellar.

### Claim 79 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The composition of any one of claims 68-78, wherein the composition further comprises lecithin.

### Claim 80 (depends on 79)

The composition of claim 79, wherein the lecithin is present at at least about 0.25% by weight of the formulation.

### Claim 81 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The composition of any one of claims 68-80, wherein the lecithin is present at at least about 1% by weight of the formulation.

### Claim 82 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The composition of any one of claims 68-81, wherein the lecithin is present at at least about 10% by weight of the formulation.

### Claim 83 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The composition of any one of claims 68-82, wherein the lecithin is present at at least about 30% by weight of the formulation.

### Claim 84 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The composition of any one of claims 68-83, wherein the lecithin is present at at least about 60% by weight of the formulation.

### Claim 85 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The composition of any one of claims 68-84, wherein the lecithin comprises phosphatidylcholine.

### Claim 86 (depends on 85)

The composition of claim 85, wherein at least some of the phosphatidylcholine comprises a phosphatidylcholine comprising a stearic diglyceride linked to a choline ester of a phosphoric acid.

### Claim 87 (depends on 85, 86)

The composition of any one of claim 85 or 86, wherein at least some of the phosphatidylcholine comprises a phosphatidylcholine comprising a palmitic diglyceride linked to a choline ester of a phosphoric acid.

### Claim 88 (depends on 85, 86, 87)

The composition of any one of claim 85-87, wherein at least some of the phosphatidylcholine comprises a phosphatidylcholine comprising an oleic diglyceride linked to a choline ester of a phosphoric acid.

### Claim 89 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The composition of any one of claims 68-88, wherein the lecithin comprises polyenylphosphatidylcholine.

### Claim 90 (depends on 89)

The composition of claim 89, wherein the polyenylphosphatidylcholine is present at between 0% and about 15% by weight of the formulation.

### Claim 91 (depends on 89, 90)

The composition of any one of claim 89 or 90, wherein the polyenylphosphatidylcholine comprises linoleic acid.

### Claim 92 (depends on 89, 90, 91)

The composition of any one of claims 89-91, wherein the polyenylphosphatidylcholine comprises dilinoleoylphosphatidylcholine.

### Claim 93 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The composition of any one of claims 68-92, wherein the formulation further comprises an emulsifier.

### Claim 94 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The composition of any one of claims 68-93, wherein the formulation further comprises a fatty acid ester.

### Claim 95 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The composition of any one of claims 68-94, wherein the formulation further comprises ascorbate palmitate.

### Claim 96 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The composition of any one of claims 68-95, wherein the formulation further comprises isopropyl palmitate.

### Claim 97 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The composition of any one of claims 68-96, wherein the formulation further comprises a transdermal penetration enhancer.

### Claim 98 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The composition of any one of claims 68-97, wherein the formulation further comprises 1,3-dimethyl-2-imidazolidinone.

### Claim 99 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The composition of any one of claims 68-98, wherein the formulation further comprises 1,2-propanediol.

### Claim 100 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The composition of any one of claims 68-99, wherein the composition has a viscosity of at least about 20,000 cP.
